A next-generation pneumococcal conjugate vaccine, PCV20, a single-dose protection is now available in India marking a new ...

Pfizer has launched its 20-valent pneumococcal conjugate vaccine (PCV20) in India, offering single-dose protection against 20 ...

Pfizer’s PCV20 offers single-shot protection against 20 pneumococcal serotypes, safeguarding adults from serious respiratory ...

Single-dose PCV20 approved for adults 18 years and older, covering 20 pneumococcal serotypes, including both invasive and non ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1, ...

The "Pneumococcal Disease - Pipeline Insight, 2025" report offers in-depth analysis of over 20 drugs and 18 companies in the Pneumococcal Disease pipeline, covering clinical and nonclinical stages.

ADMA Biologics' recent Q2 report showed that the company is working on enhancing its plasma yields by over 20% in IG output.

The United Nations Children’s Fund (UNICEF), in cooperation with the Ministry of Health, has delivered two shipments of ...

Officials estimated that 228 fewer babies younger than 3 months older were hospitalized for serious RSV infection during the peak of the season, a number they hope will increase as more women are ...

The global pneumonia diagnostics market is on track for steady expansion, with market value projected to grow from USD 613.6 ...

Vaxcyte (NASDAQ:PCVX), a biotechnology company specializing in next-generation vaccines, reported its second quarter 2025 results on August 6, 2025. The company reported a GAAP ne ...